Option chain shows key data for PharmaCielo's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PharmaCielo.

PharmaCielo (OTC:PCLOF) Stock, Option Chain

PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico. It generates the majority of its revenue in the form of the Sale of Cannabis derivative products in Colombia.

ibrahim-rifath-OApHds2yEGQ-unsplash(9)

Cannabis

Earnings

News

PCLOF

TSX:PCLO

TSXV:PCLO

Cannabis products company PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) announced on Monday financial and operational results for the three and nine months ended Sept. 30, 2024. The Toronto-based company said revenue for the third quarter totaled CA$1.3 million ($927,772), up from CA$352,000 in the prior year&#39;s period. For the nine months, total revenues reached CA$2.4 million, compared to CA$1.3 million in 2023. &#34;PharmaCielo achieved substantial revenue growth, successfully expanded into new international markets, and continued its focus on reducing costs to improve its operational efficiency,&#34; Marc Lustig, chairman and CEO of PharmaCielo, said. &#34;Our strategic position in multiple regions, coupled with an expanding product portfolio beyond CBD isolate, has enhanced our ability to serve diverse international markets and generate increased revenue.&#34;

PharmaCielo Cannabis Co. Reports 270% YoY Increase In Q3 Revenue, Confident About Profitability In 2025

Screen Shot 2024-10-24 at 13.36.47

Latin America

Regulations

Exclusives

Interview

AVCNF

CLVR

FLGC

OWPC

TSX:AVCN

Colombia&#39;s cannabis decree allows dry flower sales, but ex-official claims it won&#39;t just protect small producers—most companies may qualify.

Cannabis Flower Sales In Colombia And The Small Producer Protection Myth: Ex-Official Says Most Companies Qualify

Europe Euro rain Cannabis (M.KOS and MVelishchuk on Shutterstock)

Education

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TLRY

TSX:WEED

WEED

The Czech Republic could be missing out on hundreds of millions of euros annually as the governing coalition remains persistent in avoiding establishing a regulated marijuana market. That&#39;s according to the findings of a comprehensive study examining the possible costs and benefits of various cannabis reform models being proposed nationwide.

This European Country Could Lose $242M A Year If It Doesn&#39;t Regulate Its Marijuana Market, Study Finds

PharmaCielo Ltd

The 2024 U.S. elections didn't just reshape Washington—they reignited <a href="https://www.benzinga.com/crypto">the cryptocurrency market</a>, dominated by Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). 
Since November, cryptocurrencies have rallied an impressive 65%, and according to JPMorgan analyst Kenneth B. Worthington, this surge is less about Bitcoin's volatility and more about the promise of regulatory clarity under the incoming Donald Trump administration.
<h2 class="wp-block-heading">From Chaos To Clarity</h2>
The industry's long cry for regulatory guardrails may finally be answered. Worthington points out that Trump's presidency brings a crypto-friendly tone to Washington, positioning the digital asset space for a more legitimate future. The president-elect's pro-crypto Congress and key appointments signal a new era where the focus shifts to defining market structures and clarifying which agencies—SEC or CFTC—will call the shots.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42545419/bitcoin-ethereum-dogecoin-stay-muted-before-feds-interest-rate-decision-analyst-says-btc-in-parabolic-phase-reveals-its-duration">Bitcoin, Ethereum, Dogecoin Stay Muted Before Fed&#8217;s Interest Rate Decision: Analyst Says BTC In Parabolic Phase, Reveals Its Duration</a>
Yet, don't expect fireworks just yet. While optimism runs high, actual regulatory reforms are at least 9-12 months away. From SEC and CFTC chair confirmations to rule-making processes, it's a marathon, not a sprint. 
The most immediate impact? 
FAQs and guidance provide the market with a quick dose of clarity, even as Congress wrestles with permanent legislation, the analyst said.
<h2 class="wp-block-heading">Who's Leading The Charge?</h2>
One major piece of the puzzle remains missing: the CFTC chair nomination. 
This role will likely influence the regulation of Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), two pillars of the crypto world. 
Meanwhile, the industry eagerly awaits to see how the SEC and FDIC might ease traditional finance's entry into crypto. Without some semblance of guidance, even the most pro-crypto stance won't move the needle for banks and brokers, according to Worthington.
<h2 class="wp-block-heading">A Glimpse Into The Future</h2>
What does a more transparent crypto ecosystem look like? 
For starters, exchanges like Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) are already expanding their offerings, onboarding altcoins, and exploring auxiliary services like staking. 
Traditional finance players like Charles Schwab Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) are also eyeing their next moves, with the latter pushing for Bitcoin allocations in institutional portfolios, the analyst notes.
The bottom line? 
Regulatory clarity could transform crypto from a speculative playground to a cornerstone of financial innovation. With the Trump administration setting a bullish tone, the crypto market might finally have the chance to break free from its regulatory limbo—and investors are paying attention.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42547334/the-new-gold-seasoned-investor-ross-gerber-spots-a-pot-of-bitcoin-at-the-end-of-the-rainbow">The New Gold? Seasoned Investor Ross Gerber Spots A &#8216;Pot Of Bitcoin&#8217; At The End Of The Rainbow</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

Trading Ideas

$BTC

$ETH

COIN

HOOD

SCHW

Trump Era Will Unlock Crypto Market With Regulatory Clarity, Says Analyst

WIIM

RZLV

Rezolve AI shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $5 price target.

Morgan Stanley analyst Meta Marshall maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Equal-Weight and raises the price target from $38 to $40.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on RingCentral, Raises Price Target to $40

CARA

Cara Therapeutics shares are trading lower after the company announced it entered into an all-stock merger with Tvardi Therapeutics.

Biotech

General

SCYX

SCYNEXIS Initiates Dosing In Phase 1 TrialOof SCY-247 For Invasive Fungal Infections

Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French Regions
France is the Second-Largest Fitness Market in the EU
AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced it secured exclusive distribution in Metropolitan France and French Regions with French training and equipment brand Planet Fitness SAS. The three-year agreement also includes a minimum commitment of 162 CLMBR units, which is expected to generate more than $0.5 million in revenue.

Contracts

Global

TRNR

Interactive Strength Secures 162 Unit CLMBR Commitment And Signs Exclusive Distribution Agreement With Planet Fitness SAS For France; 3-Year Agreement Expected To Generate More Than $500K In Revenue, And Covers France And French Regions

Morgan Stanley analyst Meta Marshall maintains Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Equal-Weight and raises the price target from $86 to $96.

Morgan Stanley Maintains Equal-Weight on Zoom Communications, Raises Price Target to $96

HOLX

Hologic Entered Agreement With The CDC To Develop Analyte Specific Reagents  Of Tests To Aid In H5N1 Bird Flu Detection

Morgan Stanley analyst Lauren Lieberman maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Equal-Weight and raises the price target from $40 to $46.

FIVN

Morgan Stanley Maintains Equal-Weight on Five9, Raises Price Target to $46

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A
This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs
Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bKqvqDp4-w_R5X1AHVJRq6zSjIigPlsE0IYik8gbdCjYOVuQvIUvjafzi8W2ZX38SV6M0BFYnS8d0ZILDxmoIlWXu7BHcvwcnhWxwO_chVM=">Praxis Precision Medicines</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for relutrigine in Dravet syndrome.

PRAX

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025

Guidance

Textron Expects Inventory Valuation Charge To Reduce Adjusted EPS For 2024 By Approximately $0.12 To $0.16

CGTX

Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.

RNAZ

TransCode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Prelim. Results From First Cohort In Phase 1 TTX-MC138 Clinical Trial; Showed No Significant Safety Or Dose Limiting Toxicities In Cohort 2, Says The Dose Administered To The Third Cohort Will Be Approximately Double The Dose Administered To The Second Cohort

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alzamend.com%2F&amp;esheet=54168496&amp;newsitemid=20241218800562&amp;lan=en-US&amp;anchor=Alzamend+Neuro%2C+Inc.&amp;index=1&amp;md5=be512c5550eaad892edeafce0b331a2b">Alzamend Neuro, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.

ALZN

Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder And Post-Traumatic Stress Disorder At The Society Of Toxicology 2025 Annual Meeting And ToxExpo

Total pretax special charges related to the 2023 restructuring plan are now expected to increase from the previously announced range of $165 million to $170 million to a range of $190 million to $205 million. The increased charges of $25 million to $35 million are related to contract termination costs associated with the powersports production pause. These charges will be recorded in the fourth quarter of 2024, with additional cash outlays of $25 million to $35 million expected primarily in the first half of 2025. &nbsp;

Textron Approves Additional Actions At Industrial Segment Under 2023 Restructuring Plan

PLRZ

PolyRizon shares are trading higher after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.

CRVS

Corvus Pharmaceuticals shares are trading lower. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Morgan Stanley analyst James Faucette maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) with a Underweight and raises the price target from $60 to $65.

Morgan Stanley Maintains Underweight on Block, Raises Price Target to $65

SatixFy Communications Ltd. (the "Company" or "SatixFy") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SATX#NYSE">SATX</a>), today announced that it has regained compliance with the continued listing standards of the NYSE American LLC ("NYSE American").
On December 16, 2024, SatixFy received written notice from the NYSE American confirming that the Company has resolved the continued listing deficiencies previously referenced in NYSE American's letter, dated November 30, 2023 and set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the "Company Guide"). NYSE confirmed that the Company has demonstrated compliance with the continued listing standard for a period of two consecutive quarters as required under Section 1009(f) of the Company Guide.
SatixFy remains committed to maintaining full compliance with NYSE American listing requirements and continues to focus on its operational and financial objectives.

SatixFy Communications Ltd. Ordinary Share

SATX

SatixFy Regains Compliance With NYSE American Continued Listing Standards

The consumer end market demand for powersports products continues to remain soft. As a result, and in conjunction with its annual operating plan process, TSV has begun to pause production of its powersports products as Textron's management reviews strategic alternatives for the business.&nbsp;
Upon completion of limited production runs to satisfy customer commitments, production of TSV's powersports products will be paused indefinitely in the first half of 2025.

Textron Says It Is Pursuing Strategic Alternatives For Its Powersports Product Line Within Industrial Segment's Textron Specialized Vehicles Business - Filing

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo Ltd., reporting its financial results, highlights an operational turnaround with a focus...

PharmaCielo Optimistic Despite Fiscal Challenges

PharmaCielo reports Q1 results

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a leading cultivator and producer of cannabis extracts, has announced an anticipated re...

PharmaCielo Poised for TSXV Trading Reinstatement

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a leader in medicinal-grade cannabis cultivation and production, has announced that tra...

PharmaCielo Nears Trading Reinstatement and Secures Funding

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo has reported an improvement in its financial results for Q2 2024, with revenue increasin...

PharmaCielo's Financial Health Improves in Q2 2024

PharmaCielo GAAP EPS of -C$0.015, revenue of C$0.78M

American views on marijuana effects worsening: Gallup

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a Canadian-based global medical cannabis company, has announced a change in its financi...

PharmaCielo Shifts Fiscal Year-End and Names New Auditor

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo Ltd. has announced its plan to extend the expiry date of 9,007,200 share purchase warran...

PharmaCielo Extends Warrant Expiry to Boost Market Position

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo reported an impressive 85% year-over-year sales growth, achieving a total revenue of $2....

Comments

PharmaCielo

PharmaCielo (PCLOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga